ILC Therapeutics

ILC Therapeutics

Engineered hybrid interferons for viral and inflammatory diseases.

HQ location
Glasgow, United Kingdom
Founding location
Chapelhall, United Kingdom
Launch date
Employees
Enterprise value
$23m
Company register number
  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor investor

€0.0

round
investor

€0.0

round
N/A

€0.0

round
investor investor investor

€0.0

round
*

£2.5m

Valuation: £17.5m

Early VC
Total Funding000k

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
GBP2016201720182020202120222023
Revenues0000000000000000000000000000
% growth----317 %(126 %)-
EBITDA0000000000000000000000000000
% EBITDA margin---631 %444 %(4651 %)-
Profit0000000000000000000000000000
% profit margin---549 %408 %(4205 %)-
EV0000000000000000000000000000
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget0000000000000000000000000000

Source: Company filings or news article

Notes (0)
More about ILC Therapeutics
Made with AI
Edit

ILC Therapeutics is a UK-based biotechnology company that engineers hybrid interferons, a novel class of drugs with potentially improved therapeutic profiles. The company was founded in 2012 by Professor William H. Stimson, who also established the Department of Immunology at The University of Strathclyde, and Alistair Strachan. Professor Stimson's research into interferon subtypes and their roles as immunoregulators and antivirals led to the creation of the company's core technology.

The company's business model is centered on its proprietary platform technology which designs and develops novel hybrid interferons for diseases with significant unmet medical needs. Their commercial strategy involves seeking co-development and licensing partners for their assets as they advance through clinical stages. ILC Therapeutics operates as a semi-virtual company, utilizing external contract research and manufacturing organizations while conducting research at its own laboratory facilities near Glasgow.

Their lead product candidate, Alfacyte™, is a synthetic, broad-spectrum antiviral developed from the most effective alpha interferon subtypes. It is being developed as a therapeutic for respiratory viral infections, including Respiratory Syncytial Virus (RSV) and potential future pandemic threats like coronaviruses. Alfacyte™ is designed to have enhanced efficacy and reduced toxicity, potentially avoiding the flu-like symptoms associated with natural interferon treatments. A second candidate, Dermacyte™, targets inflammatory skin conditions like atopic dermatitis. The company has secured multiple rounds of funding, including investments from Scottish Enterprise, Eos Advisory, and Medical Incubator Japan, to advance its candidates through pre-clinical and clinical development.

Keywords: hybrid interferons, cytokine engineering, antiviral therapeutics, innate immune system, respiratory viral infections, Alfacyte, immunomodulation, biopharmaceutical, drug development, atopic dermatitis, preclinical development, respiratory syncytial virus, RSV, interferon alpha, viral diseases, inflammatory diseases, clinical trials, broad-spectrum antiviral

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo